These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22279598)

  • 1. Insulin resistance: Is it time for primary prevention?
    Mercurio V; Carlomagno G; Fazio V; Fazio S
    World J Cardiol; 2012 Jan; 4(1):1-7. PubMed ID: 22279598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal insulin signaling: early detection of silent coronary artery disease-erectile dysfunction?
    Potenza MA; Montagnani M
    Curr Pharm Des; 2008; 14(35):3737-48. PubMed ID: 19128226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players.
    Zimmet P; Boyko EJ; Collier GR; de Courten M
    Ann N Y Acad Sci; 1999 Nov; 892():25-44. PubMed ID: 10842650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular actions of insulin.
    Muniyappa R; Montagnani M; Koh KK; Quon MJ
    Endocr Rev; 2007 Aug; 28(5):463-91. PubMed ID: 17525361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin.
    Schwartz SS
    Diabetes Metab Syndr Obes; 2010 Jul; 3():243-52. PubMed ID: 21437092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and hyperinsulinemia in hypertension.
    Weidmann P; Böhlen L; de Courten M
    J Hypertens Suppl; 1995 Aug; 13(2):S65-72. PubMed ID: 8576790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperinsulinism. Causes and mechanisms].
    Del Prato S
    Presse Med; 1992 Sep; 21(28):1312-7. PubMed ID: 1332021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.
    Cersosimo E; DeFronzo RA
    Diabetes Metab Res Rev; 2006; 22(6):423-36. PubMed ID: 16506274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperinsulinemia--how innocent a bystander?
    Zimmet PZ
    Diabetes Care; 1993 Dec; 16 Suppl 3():56-70. PubMed ID: 8299479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogenic role of hyperinsulinism in macroangiopathy. Epidemiological data].
    Valensi P
    Presse Med; 1992 Sep; 21(28):1307-11. PubMed ID: 1438099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperinsulinemia--the common denominator in type II diabetes mellitus,obesity, hypertension, hypertriglyceridemia and atherosclerosis].
    Málková J; Andĕl M; Stolba P; Kimlová I
    Cas Lek Cesk; 1994 Jan; 133(2):41-5. PubMed ID: 8131178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The metabolic syndrome. Part II: its mechanisms of development and its complications].
    Pacholczyk M; Ferenc T; Kowalski J
    Postepy Hig Med Dosw (Online); 2008 Oct; 62():543-58. PubMed ID: 18936730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia.
    Flack JM; Sowers JR
    Am J Med; 1991 Jul; 91(1A):11S-21S. PubMed ID: 1867224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?
    Bender SB; McGraw AP; Jaffe IZ; Sowers JR
    Diabetes; 2013 Feb; 62(2):313-9. PubMed ID: 23349535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes.
    Patel TP; Rawal K; Bagchi AK; Akolkar G; Bernardes N; Dias DDS; Gupta S; Singal PK
    Heart Fail Rev; 2016 Jan; 21(1):11-23. PubMed ID: 26542377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
    Kim JA; Montagnani M; Koh KK; Quon MJ
    Circulation; 2006 Apr; 113(15):1888-904. PubMed ID: 16618833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.